"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Large intravenous doses of Methylene Blue (methylene blue injection) produce nausea, abdominal and precordial pain, dizziness, headache, profuse sweating, mental confusion and the formation of methemoglobin.
Use in Pregnancy
Safety for use in pregnancy has not been established. Use of Methylene Blue (methylene blue injection) in women of childbearing potential requires that anticipated benefits be weighed against possible hazards.
Read the Methylene Blue (methylene blue injection) Side Effects Center for a complete guide to possible side effects
No information provided.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 7/22/2008
Additional Methylene Blue Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.